When GLP-1 trials report

Every active phase 2+ trial of a GLP-1, incretin or amylin agent with 100 or more participants and an estimated primary completion date in the next 30 months. Dates are as filed by the sponsor on ClinicalTrials.gov. Each row links to the registry record.

A trial's primary completion date is when the sponsor expects to have the main result in hand, not when it will be published or presented — those usually follow by months. 176 tracked trials across 17 molecules carry one, 89 of them phase 3 or later, and 19 fall inside the next 90 days. Sponsors move these dates routinely and the registry overwrites the old value when they do, so a date here is a plan rather than a promise; every movement this site has observed is kept on the changes page.